clinical trials

AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial
Fierce Pharma
AstraZeneca
Imfinizi
clinical trials
immuno-oncology
Flag link:
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
Fierce Biotech
NeuroRx
NRX-101
suicidal bipolar depression
clinical trials
Flag link:
Vanda preps Hetlioz for a new market
Vanda preps Hetlioz for a new market
EP Vantage
clinical trials
Vanda Pharmaceuticals
Hetlioz
Smith-Magenis syndrome
Flag link:
Lawsuit Charges FDA, NIH With Failing to Follow Established Law for Reporting of Clinical Trial Data
Lawsuit Charges FDA, NIH With Failing to Follow Established Law for Reporting of Clinical Trial Data
BioSpace
FDA
clinical trials
NIH
Flag link:
Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials
Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials
BioSpace
Amgen
clinical trials
diversity
minorities
oncology
Flag link:
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Fierce Biotech
Ra Pharma
Soliris
clinical trials
myasthenia gravis
zilucoplan
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
Axovant dumps nelotanserin in retreat from small molecule R&D
Axovant dumps nelotanserin in retreat from small molecule R&D
Fierce Biotech
Axovant
nelotanserin
dementia with Lewy bodies
clinical trials
R&D
small molecule drugs
Flag link:
FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Endpoints
Macrogenics
FDA
bispecific antibodies
clinical trials
B7-H3 × CD3
Flag link:
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Pharmaceutical Business Review
Eisai
Alzheimer's disease
E2814
clinical trials
University College London
Flag link:
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fierce Pharma
AstraZeneca
Imfinzi
head and neck cancer
clinical trials
Flag link:
Supernus says ADHD drug trounces rivals, but shares slide
Supernus says ADHD drug trounces rivals, but shares slide
Pharmaforum
Supernus
ADHD
SPN-812
clinical trials
Flag link:
Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3
Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3
Fierce Pharma
Novartis
Xolair
ligelizumab
hives
clinical trials
Flag link:
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
Flag link:
Novartis’ partners at Conatus have another NASH setback to confess today
Novartis’ partners at Conatus have another NASH setback to confess today
Endpoints
Novartis
Conatus
emricasan
cirrhosis
NASH
clinical trials
Flag link:
Eli Lilly's former drug yields Phase 2 win for Vanda Pharma
Eli Lilly's former drug yields Phase 2 win for Vanda Pharma
Biopharma Dive
Vanda Pharmaceuticals
gastroparesis
clinical trials
Eli Lilly
tradipitant
Flag link:
Pivotal trial kicks off for Edwards Lifesciences’ Pascal mitral repair device
Pivotal trial kicks off for Edwards Lifesciences’ Pascal mitral repair device
Mass Device
devices
Edwards Lifesciences
Pascal mitral valve repair system
mitral valve
clinical trials
Flag link:
Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair
Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair
Endpoints
Novartis
hives
monoclonal antibodies
ligelizumab
clinical trials
Flag link:
Biohaven's orally dissolving tablet meets in Phase III for acute migraine
Biohaven's orally dissolving tablet meets in Phase III for acute migraine
BioCentury
Biohaven
migraines
clinical trials
BHV3000-303
Flag link:
Aprea heading for Phase III with €50M series C round
Aprea heading for Phase III with €50M series C round
BioCentury
Aprea
MDS
APR-246
clinical trials
Flag link:

Pages